WuXi XDC Partners with GeneQuantum for ADC Development
China-based WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a...
ADC / XDC
Biosion and ImmunoGen Collaborate on Cancer ADCs
China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the...
Henlius Biotech Partners with Medilink for Global ADC Development
Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with Suzhou-based Medilink Therapeutics, obtaining...
RemeGen’s RC118 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers
China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained...
Enhertu Confirmed as New Standard of Care for Breast Cancer in Phase III Study
AstraZeneca PLC (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) released the latest data supporting the...
Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...
Biocytogen and ADC Therapeutics Enter Evaluation and Option Agreement
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an evaluation and option agreement with Swiss...
Bliss Bio’s BB-1709 Accepted for Review by China’s CDE
Hangzhou-based oncology-focused clinical stage biotech Bliss Bio has announced that its clinical filing for the...
Xiling Lab Raises RMB 100 Million for ADC Development and IND Filing
Xiling Lab, a Chengdu-based drug developer specializing in catalytic synthesis technology, has reportedly raised close...
PrimeLink Bio Raises Funds for ADC Development and R&D Expansion
Shenzhen-based drug developer PrimeLink Bio has reportedly raised “hundreds of millions” of renminbi in a...
Kelun Pharma’s SKB264 Advances to Phase II Study for NSCLC
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody drug conjugate...
Kelun-Biotech’s SKB264 Receives FDA Approval for Phase II Study
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the US FDA to...
LaNova Medicines Gets NMPA Approval for LM-305 Clinical Study
Shanghai-based cancer therapy developer LaNova Medicines Ltd has announced that it has received approval from...
Novatim Immune Therapeutics Raises RMB 500M in First Financing Round
China-based tumor immunotherapy developer Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has reportedly raised close to...
Dartsbio Licenses Potential First-in-Class BsAb DS005 to Duality Biologics
China-based Dartsbio Pharmaceuticals, Ltd has announced a licensing deal with Duality Biologics, a novel modality...
Zhejiang Medicine’s ARX788 Advances to Phase II Study for HER2-Positive Cholangiocarcinoma
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has received approval from the National Medical Products...
Innovent’s CLDN18.2 ADC IBI343 Begins Phase I Trial in Australia
Innovent Biologics Inc. (HKG: 1801) has announced the first subject dosing in a Phase I...
Alphamab Oncology Gains NMPA Approval for JSKN003 Clinical Trial
Alphamab Oncology (HKG: 9966) announced that it has received approval from the National Medical Products...
CSPC’s Antibody-Drug Conjugate SYS6002 Gains CDE Approval for Clinical Study
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...
Daiichi Sankyo Initiates Global Phase II Study of DS7300 for Small-Cell Lung Cancer
Japan-based Daiichi Sankyo Inc. (TYO: 4568) has announced the first patient dosing in a global...